CINECA IRIS Institutional Research Information System

NICOLINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.714
AS - Asia 7.565
EU - Europa 4.401
SA - Sud America 834
AF - Africa 237
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 26.765
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.258
SG - Singapore 2.393
CN - Cina 2.322
IT - Italia 1.243
HK - Hong Kong 1.220
BR - Brasile 743
SE - Svezia 636
BG - Bulgaria 564
VN - Vietnam 499
CA - Canada 400
UA - Ucraina 377
TR - Turchia 364
DE - Germania 346
KR - Corea 318
FI - Finlandia 292
FR - Francia 234
RU - Federazione Russa 227
GB - Regno Unito 214
JP - Giappone 157
CH - Svizzera 149
CI - Costa d'Avorio 117
IN - India 78
BD - Bangladesh 40
IQ - Iraq 35
MX - Messico 29
AR - Argentina 28
SN - Senegal 23
SA - Arabia Saudita 22
UZ - Uzbekistan 19
ZA - Sudafrica 19
BE - Belgio 18
BJ - Benin 17
PK - Pakistan 17
NL - Olanda 14
AT - Austria 13
CZ - Repubblica Ceca 13
EC - Ecuador 13
ID - Indonesia 13
MA - Marocco 12
PY - Paraguay 12
VE - Venezuela 12
CO - Colombia 10
TN - Tunisia 10
AU - Australia 9
ES - Italia 9
GR - Grecia 9
JO - Giordania 9
PL - Polonia 9
KE - Kenya 7
EG - Egitto 6
ET - Etiopia 6
LT - Lituania 6
MY - Malesia 6
PH - Filippine 6
HU - Ungheria 5
IE - Irlanda 5
IR - Iran 5
JM - Giamaica 5
NP - Nepal 5
PE - Perù 5
CL - Cile 4
DK - Danimarca 4
IL - Israele 4
LB - Libano 4
OM - Oman 4
RO - Romania 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
BO - Bolivia 3
BS - Bahamas 3
DZ - Algeria 3
KZ - Kazakistan 3
MU - Mauritius 3
PA - Panama 3
TH - Thailandia 3
TW - Taiwan 3
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
DO - Repubblica Dominicana 2
EU - Europa 2
KG - Kirghizistan 2
LY - Libia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
Totale 26.747
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.423
Singapore 1.369
Ashburn 1.336
Ann Arbor 1.238
Hong Kong 1.213
Chandler 967
Fairfield 918
Houston 885
San Jose 569
Sofia 563
Dallas 547
Jacksonville 485
Milan 476
Shanghai 473
Beijing 432
Santa Clara 413
Seattle 377
Hefei 374
Ottawa 367
Wilmington 354
New York 337
Cambridge 336
Seoul 316
Nanjing 260
Izmir 258
Boardman 242
Princeton 229
Lawrence 220
Medford 214
Lauterbourg 185
Des Moines 167
Tokyo 150
Bern 139
Abidjan 117
Los Angeles 117
Ho Chi Minh City 114
Dearborn 101
Istanbul 93
Nanchang 90
Hanoi 86
Buffalo 79
Jüchen 75
Redondo Beach 74
Dong Ket 71
Florence 66
São Paulo 57
Kunming 56
Serra 56
Helsinki 55
San Diego 44
Shenyang 44
Chicago 40
Council Bluffs 38
Munich 36
Hebei 34
Ogden 34
Rome 34
The Dalles 34
Boulder 33
Columbus 33
Tianjin 33
Frankfurt am Main 32
Falls Church 28
Changsha 27
Rio de Janeiro 26
Dakar 23
Hangzhou 23
London 23
Redwood City 23
Pune 22
Guangzhou 21
Lancaster 20
Pisa 20
Jiaxing 19
Brussels 18
Da Nang 18
Norwalk 18
Cotonou 17
Düsseldorf 17
Orange 17
Auburn Hills 16
Orem 15
Phoenix 15
Brasília 14
Turku 14
Fuzhou 13
Lanzhou 13
Tashkent 13
Vienna 13
Washington 13
Curitiba 12
Jinan 12
Porto Alegre 12
Genoa 11
Haiphong 11
Salvador 11
Belo Horizonte 10
Changchun 10
Dhaka 10
Johannesburg 10
Totale 20.236
Salva come PNG Salva come JPEG
Nome #
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 225
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. 216
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 211
T cell-mediated immunity, eosinophils, sIL-2R, neopterin and interleukins 4, 6, 10, 12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 210
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study 208
Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs 201
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 195
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 191
Molecular markers in breast cancer: no longer a “free” run from laboratory to the clinic 188
Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease 187
Accuracy of an individual reference limit (IRL) during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel 185
Early diagnosis and treatment of breast cancer relapses 183
Additional 5-FU-LV significantly increases survival in gastrointestinal cancer 182
A rationale non-invasive schedule with tumor markers and instrumental exsaminations for “early” detection of bone metastases in breast cancer 175
Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment. 173
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 173
Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective six year study 172
Stem cells: their role in breast cancer development and resistance to treatment. 166
A meta-analysis of the performance of serum tumour markers levels for early signalling distant metastases during post-operative follow-up of disease-free breast cancer patients 163
Defining the critical hurdles in cancer immunotherapy. 163
Bone scintigraphy and tumor markers in the post-operative follow-up of breast, colorectal, prostate and renal cancer 163
Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 160
Tumor markers increase the diagnostic accuracy of skeletal metastases in breast cancer patients 159
CEA, TPA, GICA, CA 72-4 and CA 195 and their associations in the post-operative follow-up of colorectal cancer 158
Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. 158
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin (PHA) and NK cytotoxic activity of peripheral blood lymphocytes in patients (pts) mastectomized for breast cancer 157
Pilot study with subcutaneous (s.c.) low dose rIL-2 cyclically given in addition to 5-FU and leucovorin (LV) in metastatic colorectal cancer 156
Criteria to use serum tumour marker levels for early signalling distant metastases durino post-operative follow-up of disease-free breast cancer patients: laboratori and clinical aspects. 155
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 154
Lymphopressotherapy in chronic postmastectomy lymphedema 152
Postoperative monitoring of breast cancer patients with tumor markers 152
Cell mediated immunity (CMI) in breast cancer patients at the relapse 152
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin and NK cytotoxic activity of peripheral blood lymphocytes in patients mastectomized for breast cancer 152
Impact on survival of "early" detection of colorectal cancer relapses with tumor markers 151
A rational non invasive schedule with tumor markers, bone scanning (BS) and "aimed" computed tomography (CT) or skeletal x - ray for "early" detection of bone metastases in breast cancer 151
Cell mediated immunity in disease free breast cancer patients 151
Cyclic beta-interferon-interleukin-2 sequence in addition to antiestrogens significantly prolongs survival of endocrine dependent metastatic breast cancer patients 151
Comparison of Ca 549 and TPS usefulness with CEA, TPA and Ca 15.3 in the post-operative follow-up of breast cancer patients 150
Tumoral markers in the kidney cancer: preliminary results 150
Urinary markers of bone resorption in breast cancer patients 150
Microcirculation in chronic post-mastectomy lymphoedem 149
Circulating tumor cells (CTCs) in breast cancer post-operative follow-up: a preliminary comparison with serum CEA-TPA-CA15.3 tumor marker (TM) panel based monitoring. 149
Cell mediated immunity (CMI) in non relapsed breast cancer patients 146
T-cell mediated immunity (CMI) and B lymphocytes in breast cancer patients after mastectomy 144
Osteoporosis and biomaterial osteointegration 144
Prognostic indices of overall survival (OS) and response to TAM and MAP in metastatic breast cancer patients 143
Evaluation of CEA, TPA, Ca 15.3, Ca 549 and TPS in the monitoring of metastatic breast cancer 143
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patints with breast cancer and benigne pathology 143
Low s.c. rIL-2 doses cyclically given in advanced renal cancer patients 143
Atherosclerosis and cancer: common pathways on the vascular endothelium 143
RELATIONSHIP AMONG CIRCULATING LEVELS OF THYROID HORMONES TSH AND TBG AFTER THYROIDECTOMY 142
CEA, TPA, GICA, CA 72-4 and CA 195 in the post-operative follow-up of colorectal cancer 142
A rationale follow-up with CEA-TPA-CA15.3 tumor marker panel strongly decreases the conventional instrumental examinations to monitor metastatic breast cancer patients 142
Large needle aspiration biopsy (LNAB) of palpable thyroid nodules refines the two FNA cytological diagnoses of microfollicular nodule and suspected cancer 142
Large needle aspiration biopsy histology for the preoperative selection of the palpable thyroid nodule diagnosed by FNA cytology as microfollicular nodule, microfollicular nodule with atypical cells or suspected cancer 142
Usefulness of serum NSE and S-100 protein in patients with malignant melanoma: preliminary data 141
Bioabsorbable scaffold for in situ bone regeneration. 140
Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor biology 138
From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules 138
Uselfulness of serum CEA, GICA and ferritin measurement in the postoperative follow-up of renal cancer 137
In colorectal cancer a multistep therapy with subcutaneous (s.c.) low dose recombinant interleukin-2(rIL-2),5-fluorouracil (5-FU) and leucovorin(LV) prolongs the duration of responce and overall survival of patients with inoperable metastases 137
Subcutaneous (s.c.) low dose rIL-2 cyclically given increases the response rate (RR) and prolongs the response to 5-FU and LV of metastatic colorectal cancer patients (pts): an update of results 137
Emergent biomolecular markers for improving preoperative diagnosis of thyroid tumors 137
Our experience with subcutaneous (s.c.) rIL2 therapy in advanced cancer patients 136
Preoperative histological diagnosis of palpable thyroid nodules: accuracy of aspiration needle biopsy 136
Role of obesity , alcohol and smoking on bone health 135
TSH levels are affected by time of blood sampling in the follow up of levothyroxine substitution therapy: preliminary report 133
Subcutaneous (sc) low dose rIL-2 cyclically given prolongs the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 132
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial 132
Comparison Between Two Different Dynamic Methods for Evaluating CEA-TPA-CA15.3 Tumor Marker ™ Panel Specificity in the Post-Operative Follow-up of Disease-Free Breast Cancer Patients: Preliminary Results 132
TSH levels are affected by time of blood sampling in untreated euthyroid goitrous patients. 131
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients 131
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 131
Serum levels of T-lymphocyte subpopulations, eosinophils, sIL-2R, neopterin and IL-4, IL-6, IL-10, IL-12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 131
Advanced breast cancer: an update and controversies on diagnosis and therapy 131
Comparison between two groups of breast cancer patients submitted or not to a rational post-operative follow-up with tumor markers 130
Early detection of colorectal cancer relapses with tumor markers 130
In colorectal cancer a multistep therapy with subcutaneous (s. c.) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) prolongs the duration of response and overall survival of patients with inoperable metastases 130
intensive post operative follow of breast cancer patients with tumors markers: accuracy of serum MCA,Ca 15,3 and CEA, TPA,CA15.3 tumor maker panel for early detection of relapse. 130
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 130
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 130
Home therapy with low-dose s.c. rIL-2 cycles to prolong the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 128
Usefulness of a rationale post-operative follow-up of breast cancer with tumor markers 127
Prognostc value of tissue vascular endothelial growth factor in primary breast cancer 127
Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies 127
An intensive and risk-adapted follow-up with CEA-TPA-CA19.9-CA72.4 tumour marker panel and abdominal US in diagnosing operable recurrences from colorectal cancer: impact on survival. 126
Cytokines in the management of high risk or advanced breast cancer: an update and expectation 126
First Line Salvage Hormone Immunotherapy in Endocrine-Dependent Metastatic Breast Cancer 126
Cyclin D-1 prognostic value compared to axillary node status (N), ER, PgR, MIB-1 and p53 in breast cancer patients 2, 5 and more than 10 years after mastectomy. 125
Prognostic value of tissue vascular endothelial growth factor (VEGF) in primary breast cance 124
Specificity of in individual reference limit (ISL) compared with conventional cut-off during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel. 124
Therapy following “early” detection of relapse with the CEA-TPA-CA15.3 panel after mastectomy prolongs overall survival 124
Aspiration needle biopsy refines preoperative diagnosis of thyroid nodules defined at fine needle aspiration as microfollicular nodule 124
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET 124
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. 124
Standardized use of serum tumor markers (TMs) for post-operative breast cancer follow-up: an impossible task? 124
Usefulness of “early” detection of colorectal cancer relapses with tumor markers 123
Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis 123
Methodological and clinical progress in thyroid tumor markers 122
Metastatic colo rectal cancer : a pilot study with multistep therapy. 122
Totale 14.852
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021364 0 0 0 0 0 0 0 0 0 103 54 207
2021/20221.942 3 157 15 79 406 312 23 79 124 37 52 655
2022/20232.324 323 178 132 220 295 372 18 188 424 9 140 25
2023/20242.001 351 251 253 114 273 346 23 52 39 21 36 242
2024/20255.567 31 237 44 352 331 411 560 365 652 839 667 1.078
2025/20265.227 308 883 715 289 445 666 970 250 326 375 0 0
Totale 26.875